Bombesin receptor subtype (BRS)-3, a G-protein-coupled orphan receptor, shares 51% identity with the mammalian bombesin (Bn) receptor for gastrin-releasing peptide. There is increasing interest in BRS-3 because it is important in energy metabolism, glucose control, motility, and tumor growth. BRS-3 has low affinity for all Bn-related peptides; however, recently synthetic high-affinity agonists, [D-Tyr 6 /D-Phe 6 ,␤Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14), were described, but they are nonselective for BRS-3 over other Bn receptors. Based on these peptides, three BRS-3-selective ligands were developed: peptide 2, [D-Tyr ]Bn(6 -14); and peptide 4, acetyl-Phe-Trp-Ala-His-(tBzl)-piperidine-3 carboxylic acid-Gly-Arg-NH 2 . Their molecular determinants of selectivity/high affinity for BRS-3 are unknown. To address this, we used a chimeric/site mutagenesis approach. Substitution of extracellular domain 2 (EC2) of BRS-3 by the comparable gastrin-releasing peptide receptor (GRPR) domain decreased 26-, 4-, and 0-fold affinity for peptides 4, 3, and 2. Substitution of EC3 decreased affinity 4-, 11-, and 0-fold affinity for peptides 2 to 4. Ten-point mutations in the EC2 and adjacent transmembrane regions (TM2) 2 and 3 of BRS-3 were made. His107 (EC2-BRS-3) for lysine (H107K) (EC2-GRPR) decreased affinity (25-and 0-fold) for peptides 4 and 1; however, it could not be activated by either peptide. Its combination with Val101 (TM2), Gly112 (EC2), and Arg127 (TM3) resulted in complete loss-ofaffinity of peptide 4. Receptor-modeling showed that each of these residues face inward and are within 4 Å of the binding pocket. These results demonstrate that Val101, His107, Gly112, and Arg127 in the EC2/adjacent upper TMs of BRS-3 are critical for the high BRS3 selectivity of peptide 4. His107 in EC2 is essential for BRS-3 activation, suggesting amino-aromatic ligand/ receptor interactions with peptide 4 are critical for both binding and activation. Furthermore, these result demonstrate that even though these three BRS-3-selective agonists were developed from the same template peptide, 
]Bn(6 -14); and peptide 4, acetyl-Phe-Trp-Ala-His-(tBzl)-piperidine-3 carboxylic acid-Gly-Arg-NH 2 . Their molecular determinants of selectivity/high affinity for BRS-3 are unknown. To address this, we used a chimeric/site mutagenesis approach. Substitution of extracellular domain 2 (EC2) of BRS-3 by the comparable gastrin-releasing peptide receptor (GRPR) domain decreased 26-, 4-, and 0-fold affinity for peptides 4, 3, and 2. Substitution of EC3 decreased affinity 4-, 11-, and 0-fold affinity for peptides 2 to 4. Ten-point mutations in the EC2 and adjacent transmembrane regions (TM2) 2 and 3 of BRS-3 were made. His107 (EC2-BRS-3) for lysine (H107K) (EC2-GRPR) decreased affinity (25-and 0-fold) for peptides 4 and 1; however, it could not be activated by either peptide. Its combination with Val101 (TM2), Gly112 (EC2), and Arg127 (TM3) resulted in complete loss-ofaffinity of peptide 4. Receptor-modeling showed that each of these residues face inward and are within 4 Å of the binding pocket. These results demonstrate that Val101, His107, Gly112, and Arg127 in the EC2/adjacent upper TMs of BRS-3 are critical for the high BRS3 selectivity of peptide 4. His107 in EC2 is essential for BRS-3 activation, suggesting amino-aromatic ligand/ receptor interactions with peptide 4 are critical for both binding and activation. Furthermore, these result demonstrate that even though these three BRS-3-selective agonists were developed from the same template peptide, [D-Phe ]Bn-(6 -14), their molecular determinants of selectivity/high affinity varied considerably.
BRS-3 is an orphan receptor present in both the central nervous system and peripheral tissues (Fathi et al., 1993b; Ohki-Hamazaki et al., 1997; Sano et al., 2004; Porcher et al., 2005) whose role in normal physiology or pathological conditions is largely unknown. Because of its 51 and 47% amino acid homology with the human bombesin (Bn) receptors [gastrin-releasing peptide receptor (GRPR) and neuromedin B receptor (NMBR)], it is classified in this receptor family (Fathi et al., 1993b; Jensen et al., 2007) . BRS-3 is receiving increased attention because its disruption leads to obesity, diabetes, and hypertension (Ohki-Hamazaki et al., 1997) . Furthermore, from knockout and expression studies, it has been reported that the BRS-3 receptor is frequently overexpressed by various tumors (Fathi et al., 1993b; Jensen and Moody, 2006; Schulz et al., 2006) , its presence plays a role in lung tumor invasiveness (Jensen et al., 2007) , plays a role in lung injury (Jensen et al., 2007) , plays a role in regulation of insulin release (Nakamichi et al., 2004) , and may play an important role in regulating gastrointestinal motility (Porcher et al., 2005) .
At present, little is known about the pharmacology or cell biology of BRS-3, and almost nothing is known about the molecular determinants of high-affinity interaction with the BRS-3 receptor. This occurred because studies demonstrate BRS-3 has low affinity for all occurring natural Bn-related peptides as well as most synthetic bombesin-family member analogs Jensen et al., 2007) , with NMB and GRP only interacting with BRS-3 in the micromolar concentrations (Fathi et al., 1993b; Mantey et al., 1997; Jensen et al., 2007) . However, it has been possible to perform detailed pharmacological studies subsequently because recently, a synthetic Bn analog, ,␤Ala 11 ,Phe 13 ,Nle 14 ]-Bn(6 -14) peptide 5 (Table 1) , was discovered to have a high affinity for both human Pradhan et al., 1998; Jensen et al., 2007) and monkey (Sano et al., 2004) BRS-3 receptors. Subsequent studies demonstrated that this synthetic Bn peptide had a unique pharmacology because it had high affinity not only for BRS-3 receptors but also for human GRPR and NMBR as well as GRPR and NMBR in most species and the frog BB 4 receptor (Fathi et al., 1993b; Pradhan et al., 1998; Jensen et al., 2007) . Subsequent studies using this synthetic Bn analog or its Tyr 6 derivative demonstrated that hBRS-3 activation stimulated phospholipase C, phospholipase D, and tyrosine kinase cascades but did not stimulate adenylate cyclase activation Jensen et al., 2007) .
Because of its potential importance in a number of physiological and pathological processes, recently a number of studies have attended to develop BRS-3 receptor-selective ligands, using either 6 -14) as a starting point. Detailed structure-function studies identified three related peptides, which have selectivity for BRS-3 over the GRPR or the NMB receptor (Mantey et al., 2001 (Mantey et al., , 2004 (Mantey et al., , 2006 Boyle et al., 2005; Jensen et al., 2007) . However, nothing is known of the molecular basis of binding, affinity, or selectivity of these peptide agonists for BRS-3 or the molecular determinants of high-affinity interaction of any peptides with this unique orphan receptor. To gain insight into the molecular basis of high affinity for the BRS-3 and determinants of receptor selectivity, in the present study, we have investigated the ability of various nonselective and BRS-3 receptor-selective agonists (Table 1) to interact with this receptor using both a chimeric receptor approach and site-directed mutagenesis of involved receptor regions.
Materials and Methods

Materials
The following cells and materials were obtained from the sources indicated: Balb 3T3 (mouse fibroblast) cells were from the American Type Culture Collection (Rockville, MD); polyoma large T antigenexpressing Chinese hamster ovary (CHOP) cells were a gift from James W. Dennis (Samuel Lunenfeld Research Institute, Toronto, Canada) ; the mammalian expression vectors, pcDNA3 and pcDNA3.1, custom primers, restriction endonucleases (SmaI and EcoRI), penicillinstreptomycin, Lipofectamine PLUS Reagent, Opti-MEM I ReducedSerum Medium, and Geneticin-selective antibiotic (G418 Sulfate) were from Invitrogen (Carlsbad, CA); QuikChange Site-Directed Mutagenesis Kit was from Stratagene (La Jolla, CA); Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS), fetal bovine serum (FBS), and trypsin/versene solution were from Biosource International (Camarillo, CA); Na 125 I (2200 Ci/mmol) was from Amersham Biosciences (Piscataway, NJ); 1,3,4,6-tetrachloro-3␣,6␣-diphenylglycouril and dithiothreitol were from Pierce Biotechnology Inc. (Rockford, IL); myo-[2-
3 H]inositol (20 Ci/mmol) was from Amersham Pharmacia Biotech (Piscataway, NJ); formic acid, ammonium formate, disodium tetraborate, soybean trypsin inhibitor, bacitracin, and AG 1-X8 resin were from Bio-Rad (Richmond, CA); and bovine serum albumin fraction V (BSA) and HEPES were from ICN Pharmaceutical, Inc. (Aurora, OH). All other chemicals were of the highest purity commercially available.
Methods
Preparation of Peptides. The peptides were synthesized using standard solid-phase methods as described previously (Mantey et al., 2006) . In brief, solid-phase syntheses of peptide amides were carried out using Boc chemistry on methylbenzhydrylamine resin (Advanced ChemTech, Louisville, KY) followed by hydrogen fluoride cleavage of free peptide amides. The crude peptides were purified by preparative high-performance liquid chromatography on columns (2.5 ϫ 50 cm) of Vydac C18 silica (10 m), which was eluted with linear gradients of acetonitrile in 0.1% (v/v) trifluoroacetic acid. Homogeneity of the peptides was assessed by analytical reverse-phase high-performance liquid chromatography, and the purity was usually 97% or higher. Amino acid analysis (only amino acids with primary amino acid groups were quantitated) gave the expected amino acid ratios. Peptide molecular masses were obtained by matrix-assisted laser desorption mass spectrometry using a Voyager-DE Pro machine (Applied Biosystems, Foster City, CA), and all corresponded well with calculated values. ]Bn-(6 -14) (peptide 1), were equipotent, each had high affinity for BRS-3, GRPR, and NMBR, and the selective BRS-3 ligands (peptides 2-4, Table 1) had the greatest difficulty in distinguishing BRS-3 from GRPR (Mantey et al., , 2001 (Mantey et al., , 2004 (Mantey et al., , 2006 ; therefore, we examined the molecular basis of affinity of these peptides for BRS-3 and GRPR. Because the molecular basis for the selectivity of various BRS-3-preferring ligands was being investigated, both BRS-3 receptor loss-of-affinity and GRPR gain-of-affinity mutants for selective BRS-3 compounds were made, as well as various point mutants and combination point mutants in BRS-3. Because the expression level and affinity of BRS-3 for some radiolabeled and unlabeled Bn peptides can be so low that pharmacological studies are limited , an arginine in position 127 was substituted for glutamine (the comparable amino acid from GRPR) in transmembrane region 3 of BRS-3, which has been shown to increase GRP affinity and/or receptor expression allowing radioligand studies to be done Nakagawa et al., 2005) . This receptor, [R127Q]BRS-3 (BRS-3*), was used in all studies with BRS-3. To construct loss-of-affinity mutants, the cDNA of human BRS-3 (BRS-3) in pCD2 was used, which was a gift from Eduardo Sainz and James F. Battey (Laboratory of Molecular Biology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD). The human hBRS-3 cDNA was inserted into pcDNA3.1 ϩ at the EcoRI site, and BRS-3 mutant receptors were constructed by using the QuikChange Site-Directed Mutagenesis Kit, following the manufacturer's instructions, with minor modifications. The mouse GRPR used in this study was identical to that described previously (Fathi et al., 1993a; Akeson et al., 1997) . Nucleotide sequence analysis of the entire coding region was performed. Chimeric receptors were made using human BRS-3 and mouse GRPR, which has been used extensively in several mutagenesis studies and allows comparison with previous results (Fathi et al., 1993a; Akeson et al., 1997; Tokita et al., 2001b; Nakagawa et al., 2005) . The mouse GRPR has 89% amino acid homology to the human GRPR, with most of the differences occurring in the amino terminus of the two receptors, an area that has been shown previously not to be important for high-affinity agonist peptide ligand binding (Fathi et al., 1993a; Tokita et al., 2001b) . In the critical areas of the extracellular (EC) 2 and surrounding domains examined in this study in detail, the mouse and human GRPRs have 97% homology, and the two amino acid differences were conservative changes (i.e., mouse had a Val92 instead of I in the human and a Lys101 instead of Arg in the comparable position in the human GRPR).
Growth and Maintenance of Cells. Balb 3T3 cells were grown in DMEM containing 10% (v/v) FBS, 100 units/ml penicillin, and 100 g/ml streptomycin. CHOP cells were grown in DMEM containing 10% (v/v) FBS, 100 units/ml penicillin, 100 g/ml streptomycin, and 200 g/ml G418. All cells were maintained at 37°C in a 5% CO 2 atmosphere. Cells were split every 3 to 4 days at confluence after detaching the cells with trypsin/versene solution.
Cell Transfections and Isolation of Stable Cell Lines. CHOP cells, which contain no native GRP receptors, were used for transient transfection studies, and Balb 3T3 cells were used for stable transfection studies because previous studies demonstrated bombesin receptors have similar pharmacology and cell biology to wild-type receptors when expressed in these cells . CHOP and Balb 3T3 all were seeded in a 10-cm tissue culture dish at a density of 0.8 and 0.5 ϫ 10 6 cells/dish, respectively, and grown overnight at 37°C in growth medium. On the following morning, 5 g of plasmid DNA was transfected to cationic lipid-mediated method using 30 l of Lipofectamine reagent and 20 l of PLUS reagent in Opti-MEM I Reduced-Serum Medium for 3 h at 37°C. At the end of the incubation period, the medium was replaced with each growth medium. CHOP cells were maintained at 37°C in a 5% CO 2 atmosphere and were used 48 h later for binding assays. Transfected Balb 3T3 cells were selected for resistance to aminoglycoside G418 as described previously and were cultured in DMEM supplemented with 10% fetal bovine serum with 200 g/ml G418.
Preparation of 125 I-Peptide 1. 125 I-[Peptide 1] (Table 1) has a Tyr and could be radiolabeled; therefore, it was used in all binding studies at a specific activity of 2200 Ci/mmol and was prepared by a modification of methods described previously . In brief, 0.8 g of 1,3,4,6-tetrachloro-3␣,6␣-diphenylglycouril (in 0.01 g/ml chloroform) was transferred to a vial, dried under a stream of nitrogen, and washed with 100 l of KH 2 PO 4 (pH 7.4). To the reaction vial, 20 l of 0.5 M KH 2 PO 4 , pH 7.4, 8 g of peptide in 4 l of water, and 2 mCi of (20 l) Na 125 I were added, mixed gently, and incubated at room temperature for 6 min. The incubation was stopped by the addition of 100 l of distilled water. Radiolabeled peptide was separated using a Sep-Pak (Waters, Milford, MA) and high-performance liquid chromatography as described previously Tokita et al., 2001a) . Radioligand was stored with 0.5% BSA at Ϫ20°C.
Whole-Cell Radioligand Binding Assays. Binding studies to expressed plasmid DNAs were performed as described previously (Tokita et al., 2001a,b) . In brief, 48 h after transient transfection with Lipofectamine, disaggregated transfected cells were incubated for 1 h at 21°C in 250 l of binding buffer containing 24.5 mM HEPES, pH 7.4, 98 mM NaCl, 6 mM KCl, 2.5 mM KH 2 PO 4 , 5 mM sodium pyruvate, 5 mM sodium fumarate, 5 mM sodium glutamate, 2 mM glutamine, 11.5 mM glucose, 0.5 mM CaCl 2 , 1.0 mM MgCl 2 , 0.01% (w/v) soybean trypsin inhibitor, 0.2% (v/v) amino acid mixture, 0.2% (w/v) BSA, and 0.05% (w/v) bacitracin with 50 pM 125 I-[peptide 1] (2200 Ci/mmol) (Table 1) in the presence of the indicated concentration of unlabeled peptides. Although GRPR expression varying as much as 160-fold (Jensen et al., 2007) has been shown not to alter receptor affinity or potency under the experimental conditions used in this study, as an added precaution to correct for any differences in ligand bound by different mutant GRPR, binding results with each mutant receptor were compared only with results with wild-type GRPR or BRS-3 receptor-containing cells binding similar amounts of ligand. This was accomplished by varying the cell concentration between 0.05 and 4 ϫ 10 6 cells/ml for each mutant receptor so that Ͻ20% of the total added radioactive ligand was bound during the incubation and the results compared with cells transfected with wild-type GRPR or BRS-3 receptor adjusted in concentration to bind a similar amount of ligand. After the incubation, 100-l aliquots were added to 400-l microcentrifuge tubes (PGC Scientific, Frederick, MD), which contained 100 l of binding buffer to determine the total radioactivity. The bound tracer was separated from unbound tracer by pelleting the cells through the binding buffer by centrifugation at 10,000g in a Microfuge E (Beckman, Fullerton, CA) for 3 min. The supernatant was aspirated, and the pelleted cells were rinsed twice with a washing buffer that contained 1% (w/v) BSA in PBS. The amount of radioactivity bound to the cells was measured in a Cobra II Gamma counter (Packard Instruments, Meriden, CT). Binding was expressed as the percentage of total radioactivity that was associated with the cell pellet. All binding values represented saturable binding (i.e., total binding minus nonsaturable binding). Nonsaturable binding was defined as the amount of binding that occurred with 1 M peptide 1 (Table 1) in the incubation solution. Nonsaturable binding was Ͻ15% of the total binding in all experiments. Each point was measured in duplicate, and each experiment was replicated at least four times. Calculation of affinity was performed by determining the IC 50 using the curve-fitting program KaleidaGraph (Synergy Software, Reading, PA). The Student's t test was used to determine the statistical significance of differences in affinity of each chimera, point, and combination point mutant receptors compared with its own wild type receptor, binding similar amounts of radioligand.
Measurement of Inositol Phosphates. The ability of peptide 4, the most selective for BRS-3, to activate the various mutant receptors and wild-type receptor was examined and compared with the ability of the prototype peptide 5. Peptide 5 was used for these studies because it has an N-terminal Phe similar to peptide 4, whereas the other prototype peptide, i.e., peptide 1, has a Tyr in this position similar to peptides 2 and 3 (Table 1 ) and thus was used for the binding studies. Changes in total [
3 H]inositol phosphates (IPs) was measured as described previously . In brief, BRS-3*-, GRPR-, chimeric-, point-, or combination point mutanttransfected Balb 3T3 cells were subcultured into 24-well plates (5.0 ϫ 10 4 cells/well) in regular propagation media and then incubated for 24 h at 37°C in a 5% CO 2 atmosphere. The cells were then incubated with 3 Ci/ml myo- [2- 3 H]inositol in growth media supplemented with 2% FBS for an additional 24 h. Before assay, the 24-well plates were washed by incubating for 30 min at 37°C with 1 ml/well PBS, pH 7.0, containing 20 mM lithium chloride. The wash buffer was aspirated and replaced with 500 ml of IP assay buffer containing 135 mM sodium chloride, 20 mM HEPES, pH 7.4, 2 mM calcium chloride, 1.2 mM magnesium sulfate, 1 mM EGTA, 20 mM lithium chloride, 11.1 mM glucose, and 0.05% (w/v) BSA and incubated with or without any of the peptides studied. After 60 min of incubation at 37°C, the experiments were terminated by the addition of 1 ml of
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at ASPET Journals on April 10, 2017 jpet.aspetjournals.org ice-cold 1% (v/v) hydrochloric acid in methanol. Total [ 3 H]IP was isolated by anion exchange chromatography as described previously . In brief, samples were loaded onto Dowex AG1-X8 anion exchange resin columns, washed with 5 ml of distilled water to remove free [ 3 H]inositol, then washed with 2 ml of 5 mM disodium tetraborate/60 mM sodium formate solution to remove [ 3 H]glycerophosphorylinositol. Two milliliters of 1 mM ammonium formate/100 mM formic acid solution was added to the columns to elute total [ 3 H]IP. Each eluate was mixed with scintillation cocktail and measured for radioactivity in a scintillation counter.
Modeling of the hBRS-3 Receptor. Molecular modeling was performed as described previously (Nakagawa et al., 2005) . In brief, the primary sequence of the hBRS-3 receptor was input into the Swiss-PDB Viewer, DeepView, and a suggested homology modeling template, 1U19 (Okada et al., 2004) , a crystal structure of bovine rhodopsin at 2.2-Å resolution, downloaded from the PDB archives. The crystal structure of bovine rhodopsin (1U19) was loaded into Deep View, the sequence of hBRS-3 was threaded onto the structure, and EC2 and the adjacent ends of the helical transmembrane domains [i.e., transmembrane (TM) 2 and TM3] were aligned onto the structure of bovine rhodopsin. To accommodate the longer EC2 loop region of hBRS-3 relative to the shorter EC2 loop of 1U19, the central loop residues were excised. The model of hBRS-3 was imported into SYBYL 7.3 (Tripos International, St. Louis, MO). The extraneous loop regions were removed, and the ends of the helical transmembrane regions were capped. The ␣-carbon atoms of the transmembrane regions were immobilized, and the remaining atoms were relaxed through extensive energy minimization using the AMBER99 force field (Case et al., 2005) . Candidates for the three-dimensional structure of the EC2 loop were generated by the COMPOSER module of SYBYL, which produced 25 EC2 model loop candidates. Each of the hBRS-3/EC2 models were optimized by energy minimization. The resulting structures were examined and fell into approximately five topological categories. These were further relaxed by molecular dynamics at reduced temperature (20 ps, 100 K) and finally reminimized. The putative binding sites of these EC2 loop models were visualized by the SiteID module in SYBYL (Tripos International). The models were solvated with water (solvation algorithm, two layers), and water molecules capable of defining a continuous cluster within 4 Å of the protein were visualized as a surface. Amino acid residues within interaction distance (4 Å) of the solvent accessible region were labeled. The models were examined and found to exhibit a wide range of possible conformations for the extracellular EC2 loop region, but with similar energies and the expected conformations for each of the loop amino acids from Ramachandran plots. One EC2 loop (5) was determined to best fit the experimental data and is shown in Fig. 5 . In this figure, the solvent-accessible interior of the extracellular region of the transmembrane receptor is indicated as a gray shape. This central portion of the receptor may accommodate and bind ligands. Solvent-accessible amino acid residues within interaction distance (4 Å) of this interior space are shown as ball and stick models, with the residues identified in this work as important for binding colored orange.
Results
Wild-Type BRS-3, BRS-3*, and GRPR. To explore the molecular basis for the selectivity of three recently described synthetic Bn analogs (peptides 2-4, Table 1 ) for the hBRS-3 receptor over other Bn receptors (GRPR, NMBR) (Mantey et al., 2001 (Mantey et al., , 2004 (Mantey et al., , 2006 Boyle et al., 2005) , both loss-of-affinity and gain-of-affinity chimeric receptors as well as receptors with point mutations were made ( Figs. 1-3 ; Tables 2 and 3) . These chimeric receptors were made using human BRS-3 and mouse GRPR, which has been used extensively in previous mutagenesis studies and allows comparison with previous results (Fathi et al., 1993a; Akeson et al., 1997; Tokita et al., 2001b; Nakagawa et al., 2005) . Affinities and potencies for Table 1 ), which were used as the starting point for the development of the BRS-3-selective ligands because they are the only known ligands to have high affinity for human and monkey BRS-3 receptors Pradhan et al., 1998; Sano et al., 2004) . Similar to reported in other studies Pradhan et al., 1998) , peptide 1 showed a high affinity for the human BRS-3 receptor (IC 50 , 0.0027 M) and BRS-3*([R127Q]BRS-3) (IC 50 , 0.0022 M) as well as for GRPR (IC 50 , 0.0009 M) (Table 2) , which allowed it to be radiolabeled and used as a universal ligand for all receptor mutation studies. Using 125 I-peptide 1, related BRS-3-selective peptides (peptides 2-4) were found to have 61-, 35-, and 77-fold higher affinity for BRS-3* over GRPR ( Fig. 1 ; Table 2 ). Even at a concentration of 30 M, peptide 4 interacted only minimally with GRPR ( Fig. 1; Table 2 ). Extracellular Chimeric Receptors. Chimeric human BRS-3 and mouse GRPRs were made by substituting extracellular domains to explore the BRS-3 selectivity of peptides 2 to 4. Three loss-of-affinity BRS-3 chimeric receptors were made by substituting the extracellular domains of GRPR for the comparable domains in BRS-3* (Fig. 1) , and three potential gain-of-affinity GRPR chimeras were made by substituting the extracellular domains of BRS-3 for the comparable domain in GRPR (Fig. 2) .
With the loss-of-affinity BRS-3* receptor chimeras, the substitution of EC2 in the BRS-3* by the comparable domain of GRPR decreased affinity for peptide 4 by 26-fold (from 1.3 Ϯ 0.1 to 33.1 Ϯ 1.2 M) ( Fig. 1; Table 2 ). In contrast, the substitution of EC3 or EC4 of GRPR in BRS-3* did not alter the affinity of peptide 4 for BRS-3* ( Fig. 1; Table 2 ). In the case of peptide 3, not only did the replacement of the EC2 of BRS-3* with the comparable GRPR domain produce a decrease of 4.3-fold in affinity (from 0.08 Ϯ 0.01 to 0.34 Ϯ 0.03 M) ( Fig. 1; Table 2 ), but also the substitution of the EC3 reduced the affinity for peptide 3 by 11-fold (from 0.08 Ϯ 0.01 to 0.85 Ϯ 0.07 M) ( Fig. 1; Table 1 ). In contrast, with peptide 2, which closely resembles peptide 3 in structure (Table 1) , only the substitution of the EC3 caused a loss-of-affinity of 3.6-fold (0.0033 Ϯ 0.0001-0.0120 Ϯ 0.001 M) ( Fig. 1; Table  2) ; however, the substitution of EC2 or EC4 had no effect (Table 2) .
When the reverse study was performed by substitution in the GRPR, the extracellular domains (EC) of BRS-3, to attempt to gain affinity, peptide 4 showed the greatest effect with the substitution of the EC2 of BRS-3 into GRPR, by increasing its affinity 14.5-fold (from Ͼ100 to 6.9 Ϯ 0.2 M) ( Fig. 2; Table 2 ). In contrast, the substitution of the EC3 and EC4 extracellular domains of BRS-3 with those from GRPR had no effect in peptide 4 affinity ( Fig. 2; Table 2 ). With peptide 3, the substitution of the EC2 resulted in an increment in the affinity by 3.1-fold (from 2.8 Ϯ 0.1 to 0.91 Ϯ 0.07 M) ( Fig. 2; Table 2 ). In contrast, substitution of the EC3 showed the most important effect with peptide 2 by increasing the affinity 9.5-fold (from 0.200 Ϯ 0.004 to 0.021 Ϯ 0.001 M) ( Fig. 2; Table 2 ). The differences seen with peptides 2 to 4 with the loss-of-affinity and gain-of-affinity chimeric receptors were not due to a global alteration of receptor affinity because each chimera receptor retained high affinity for each of peptides 1 and 5 or one of the BRS-3-selective ligands ( Figs. 2 and 3 ; Table 2 ).
These results show that the location of receptor domains most important for determining BRS-3 selectivity of these three peptides have important differences, even though each Fig. 2 . Affinities of peptides 2 to 4 for wild-type GRPR, extracellular chimeric GRPRs, and wild-type BRS-3 expressed in CHOP cells (gain-of-affinity chimeras). Diagrams of the chimeric receptors formed are shown at the top. The chimeric GRPRs were formed by replacing each of the extracellular domains of GRPR by the comparable domain of BRS-3 one at a time. Results are expressed as the percentage of the saturable binding seen with no peptides 2 to 4 present that occurred when the indicated concentration of peptides 2 to 4 was present. Each point is the mean from at least five separate experiments, and in each experiment, each point was measured in duplicate. EC2-, e3-, and e4-BRS-3 refer to the substitution of this extracellular domain of BRS-3 for the comparable extracellular domain in GRPR. The arrows indicate large changes in affinity from the wild-type GRPR.
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EC2 of BRS-3 and Adjacent TM Region Mutants (Loss-of-Affinity Point and Combination Mutants).
Because the selectivity of the related peptides 3 and 4 were both influenced by differences in the EC2 of BRS-3 and GRPR, we wanted to determine whether the molecular basis for this was similar with these two peptides. To investigate further the molecular basis for the selectivity of peptides 4 and 3, we attempted to determine which specific amino acid(s) are responsible for the high affinity of both peptides for BRS-3 by analyzing the amino acid(s) differences and similarities in the EC2 domain and adjacent TM regions of these two receptors (Fig. 3, top) . The two receptors in this region (Fig. 3, top ) differed in 10 amino acid(s), occurring at positions 98, 101, 106 to 107, 111 to 112, 122 to 124, and 127 of BRS-3, which are comparable with positions 92, 95, 100 to 101, 105 to 106, 116 to 118, and 121 of GRPR (Fig. 3, top) . To study the 10 amino acid(s) differences, we first made 10 BRS-3 losses of affinity point mutants by substituting in BRS-3 the comparable different amino acid from GRPR.
For peptide 4, the substitution of lysine instead of histidine at position 107 (H107K) in the EC2 of BRS-3* produced the greatest effect, decreasing the affinity by 26-fold (33.1 Ϯ 1.2 Fig. 3 . Effect of various point mutations alone or in combination in the second extracellular domain and adjacent transmembrane domains BRS-3* on affinity for peptides 3 and 4. Top, alignment of amino acids sequences in the second extracellular domain or adjacent transmembrane regions of GRPR and BRS-3. The boxes indicate divergent amino acids between these two receptors in these regions. Shown are the 10 BRS-3* mutants made to explore the importance of 10 amino acid differences for determining selectivity of peptides 4 and 3. Arrows indicate that position of the point mutations made in BRS-3* by substituting into BRS-3* the divergent amino acid from the comparable position in GRPR. Middle and bottom, affinities of peptides 4 and 3 for BRS-3*, second extracellular domain or adjacent TM, or point and combination point mutants of BRS-3* expressed in CHOP cells (BRS-3* loss-of-affinity point and combination point mutants). Results are expressed as the percentage of the saturable binding seen with no peptides 3 or 4 present that occurred when the indicated concentration of peptides 3 or 4 was present. Each point is the mean from at least five separate experiments, and in each experiment, each point was measured in duplicate. The arrows indicate large changes in affinity of the BRS-3* by the mutations. [e2-GRPR]BRS-3 refers to the substitution of the second extracellular domain from GRPR into the comparable location in BRS-3. (Fig. 3, middle ; Table 3 ). This decrease in the affinity for peptide 4 was the same extent seen with the substitution of the whole EC2 domain in BRS-3 by the comparable domain of GRPR (33.1 Ϯ 1.3 M) (Table 3 ). Point mutation [V101A] (3.2 Ϯ 0.1 M) in TM2 or [G112R] (4.8 Ϯ 0.1 M) in EC2 of BRS-3* (Fig. 3, middle ; Table 3 ) caused only a loss of 3-to 4-fold in the affinity of peptide 4 for BRS-3* (Fig. 3, middle S124P] in TM3 of BRS-3* had no effect on the affinity of peptide 4 for BRS-3* (Fig. 3, middle; Table 3 ).
With peptide 3, the largest decrease in affinity was seen with the substitution of [H107K] in EC2 of BRS-3* (Fig. 3 , middle; Table 3 ), which resulted in a 5-fold decrease (0.35 Ϯ 0.01 M), which was similar to the decrease caused by the substitution of [V101A] (0.36 Ϯ 0.01 M) in TM2 and the whole replacement of EC2 domain of BRS-3 (0.34 Ϯ 0.03 M) (Table 3 ). Point mutations [L98V] in TM2 or [T106S] in EC2 of BRS-3* resulted in small (2-fold) decreases in the affinity of peptide 3 for BRS-3 ( Fig. 3, middle; Results are calculated from data in Figure 3 as described under Materials and Methods. Point and point combination mutants refer to the BRS-3* receptor in which the indicated amino acid(s) of BRS-3* was replaced by the comparable amino acid of GRPR. jpet.aspetjournals.org not affect the affinity of peptide 3 for the BRS-3* receptor (0.08 Ϯ 0.01 M) (Fig. 3, middle ; Table 3) . To explore the possible affect of multiple amino acid substitutions, we next made mutant BRS-3*s with combinations of these point mutations. With peptide 4, the triple mutant [V101A, H107K, G112R] in the BRS-3 receptor caused the largest effect (Ͼ100 M) (Fig. 3, bottom; Table 3 ), showing almost a complete loss-of-affinity, which is similar to its affinity for the native GRPR. Neither of the double combinations of point mutants, which included the substitution [H107K], including [V101A, H107K] (34.7 Ϯ 2.1 M) or [H107K, G112R] (36.3 Ϯ 2.2 M) (Fig. 3, bottom; Table 3 ) showed a greater decrease in the affinity than that caused by the substitution of [H107K] alone (33.1 Ϯ 1.2 M) ( Table 2 ). However, an additive effect for the loss-of-affinity of peptide 4 for BRS-3* was produced by the double mutant [V101A, G112R] (15.1 Ϯ 0.7 M) (Fig. 3, bottom ; Table 3 ).
With peptide 3, neither the combination of two point mutants compared with either mutation alone (Table 3 ) in the EC2 domain that affected its affinity [T106S, H107K] (0.42 Ϯ 0.02 M) (Fig. 3, bottom ; Table 3 ) nor combination of the two TM2 point mutations that altered its affinity [L98V, V101A] (0.36 Ϯ 0.03 M) alone had an additive effect ( Fig. 3, bottom ; Table 3 ). The triple mutant [V101A, T106S, H107K] had a marked effect, decreasing the affinity by 12.5-fold (1.0 Ϯ 0.1 M) (Fig. 3, bottom; Table 3 ), which was not different from [L98V, V101A, T106S, H107K] (0.93 Ϯ 0.05 M) (Fig. 3 , bottom; Table 3 ).
Stimulation of Phospholipase C. To determine the effect of these receptor mutations on activation of the GRPR or BRS-3 receptor, which are coupled to phospholipase C Jensen et al., 2007) , we determined the ability of the most selective peptide, peptide 4, to stimulate [ 3 H]IP formation in BRS-3*-, GRPR-, chimeric-, point-, or combination mutants-transfected Balb 3T3 cells ( Fig. 4; Table 4 ). Because peptide 4 has a Phe at the amino terminus instead of a Tyr, as seen in peptides 2 and 3 (Table 1) , we compared the results from peptide 4 with those of [D-Phe 6 ,␤Ala 11 , Phe 13 ,Nle 14 ]Bn-(6 -14) (peptide 5) instead of the D-Tyr 6 analog (peptide 1) ( Table 1) . Peptide 5 caused an 1358 Ϯ 199 dpm increase in [ 3 H]IP, and the stimulation occurred in a concentration-dependent manner ( Fig. 4 ; Table 4), with a halfmaximal effect in [ 3 H]IP GRPR at 0.005 Ϯ 0.001 M and for BRS-3* at 0.012 Ϯ 0.001 M. Peptides 5 and 1 were equipotent (data not shown).
Single-point mutants [V101A] in TM2, or [G112R] in EC2 or the combination [V101A, G112R] in BRS-3* had no effect on the efficacy or potency of the nonselective agonist, peptide 5, for stimulating an increase in [ 3 H]IP (Fig. 4, left ; Table 4 ). In contrast, the point mutant [H107K] in the EC2 of BRS-3* or replacement of the EC2 of BRS-3* by that from GRPR resulted in receptors that were not able to stimulate [ 3 H]IP, even at concentrations of agonist as high as 10 M (Fig. 4,  left; Table 4 ), even though they had both retained high binding affinity for peptide 1 (Tables 2 and 3) .
Peptide 4 showed high affinity, high potency, and selectivity for activating the BRS-3* receptor (0.14 Ϯ 0.01 M) (Fig.  4; Table 4) ; however, even at concentrations as high as 10 M, it did not activate GRPR (Fig. 4, right; Table 4 (Fig. 4, right Fig. 4, right ; Table 4 ).
Molecular Modeling of the BRS3 Receptor. To attempt to gain additional insight into why the different amino acids in the hBRS-3 receptor EC2 and adjacent transmembrane regions are important for high affinity and selectivity for peptide 4, the most selective agonist, and to a lesser extent for peptide 3, three-dimensional modeling of this region of the hBRS-3 receptor was performed (Fig. 5) . Because the mutagenesis studies demonstrated the importance of residues Val101, His107, Gly112, and Arg127 in the binding of peptides 3 and 4 to the hBRS-3 receptor, the environment of these crucial residues was investigated by molecular modeling. The primary sequence of hBRS-3 was entered into the Swiss-PDB Viewer, DeepView (Nakagawa et al., 2005) , and a search for suitable homology templates located a high-resolution structure of bovine rhodopsin 1U19 (Okada et al., 2004) . Because the length of extracellular domain EC2 was greater in hBRS3 than in 1U19, it was excised. The model of the transmembrane region of the receptor was exported to the SYBYL 7.3 molecular modeling suite (Tripos International), and the homology modeling COMPOSER module was used to build candidates for the EC2 loop. This generated 25 potential loop conformations based on the crystal structure of homologous protein sequences. The ␣-carbons of the transmembrane regions were constrained, and these loop models were optimized by energy minimization. Further optimization of the loops by constrained molecular dynamics followed by energy minimization produced loop models in which all amino acids were in favored positions in a Ramachandran plot. Inspection of these models showed that they fell into approximately five conformational categories. The potential binding sites in these models were probed using the SiteID module of SYBYL. Each model was solvated with water, and clusters of water molecules within interaction distance of the protein interior were defined. This produced an estimate of the solvent-accessible interior of the transmembrane receptor and which amino acids were solvent exposed and thus capable of interaction with a potential ligand. These static models clearly illustrated the flexibility of the solvated EC2 region of the receptor and the conformational space available to the residues determined in this study to be important for binding, His107 and Gly112. The remaining residues (Leu98, Val101, Leu123, Arg127) were located on the relatively fixed transmembrane regions adjacent to EC2 and were oriented toward the solvent-accessible interior of the receptor. In a cell, these membrane-bound receptors are in motion in a fluid environment in which the conformation of the binding site may be influenced by interaction with a ligand. However, static modeling can give insight into the location and accessibility of the important amino acids within the binding site and potentially guide the development of new agonists.
The EC2 loop model that most closely fitted the results of the mutagenesis studies is shown in Fig. 5 . In this figure, the transmembrane domains are shown as colored helices with the important extracellular EC2 loop (yellow) between TM2 (cyan) and TM3 (white). The model revealed the presence of a large solvent-accessible cavity within the transmembrane domain/extracellular domain interface, with potential interactions between a ligand and the interior-located transmembrane moieties and the flexible extracellular domains (gray area, Fig. 5 ). Seven of the 10 amino acids, which differed in this region between BRS3 and GRPR and were examined in this study (Leu98, Val101, His107, Glu111, Gly112, Leu123, Arg127) , were found to be within 4 Å of the proposed binding pocket. Alteration of four (Val101, His107, Gly112, Arg127) of the seven amino acids studied within 4 Å of the binding pocket caused the most significant decrease in affinity when present alone (3-26-fold), and the combination of all the members of this group caused a greater than additive decrease in affinity of peptide 4 for hBRS-3, showing almost a complete loss-of-affinity. These four important amino acids are highlighted in orange in Fig. 5 . All four of these important amino acids had their backbone residues orientated toward the interior of the receptor toward the binding pocket and thus would be available to interact with a ligand in the putative binding site. In contrast, the other three amino acids studied (T106S, Val122, Ser124), which were not im- Fig. 4 as described under Materials and Methods. Fold increase refers to the maximal stimulation seen with 1 M peptide 5 expressed as a ratio (experimental/control). EC 50 is the concentration of the indicated peptide causing half-maximal stimulation seen with 1 M peptide 5. Results are the mean Ϯ S.E.M. of four experiments. BRS-3*, ͓R127Q͔BRS-3; point and combination mutants refer to the BRS-3* receptor in which the indicated amino acid(s) of BRS-3* was replaced by the comparable amino acid of GRPR. The interior of the extracellular solvent-accessible region of the receptor is indicated as a gray shape. This central portion of the transmembrane receptor may accommodate and bind ligands. Solvent-accessible amino acid residues within interaction distance (4 Å) of this binding pocket are shown as ball and stick models, with the residues identified in this work as important for binding colored orange (Val101, His107, Gly112, and Arg127). Residues Leu98, Val101, His107, Glu111, and Gly112, which differed between BRS-3 and GRPR (Fig. 3) , are within 4 Å of the binding pocket.
portant for peptide 4 selectivity, are farther than 4 Å of the binding pocket and oriented to the exterior of the receptor model. In the case of peptide 3, the situation is slightly different. Binding results showed the implication of four residues (Leu98, Val101, Thr106, His107) in the affinity of peptide 3 for BRS-3. In our model, three of these amino acids (Leu98, Val101, His107) are situated in the hypothetical binding pocket, within 4 Å, which could confirm their implication in the affinity of the selective compound.
Discussion
This study was undertaken to provide insight into the molecular basis for agonist high-affinity selectivity for human BRS-3 (Mantey et al., 2001 (Mantey et al., , 2004 (Mantey et al., , 2006 Boyle et al., 2005) . Nothing is known of the determinants of high-affinity selectivity for BRS-3. This has occurred because it is an orphan receptor; however, it is classified in the bombesin receptor family because of its high homology with the two mammalian members of this family (i.e., GRPR, NMBR) (Fathi et al., 1993b; Jensen et al., 2007) . Furthermore, because of its low affinity for all naturally occurring Bn-related peptides Jensen et al., 2007) (Mantey et al., 2001 (Mantey et al., , 2004 (Mantey et al., , 2006 Boyle et al., 2005) , and this study explores the molecular determinants of their selectivity.
A number of our results show differences primarily in the EC domains, but also to a lesser extent in the upper TM domains of bombesin receptors, play important roles in the selectivity of these peptide agonists for BRS-3. However, the extent of their importance and the specific receptor domains involved differ for the different BRS-3-preferring agonists. First, BRS-3 chimeric loss-of-affinity studies demonstrated only that substitution of EC2 of BRS-3 produced a markedly decrease in affinity of peptide 4, which was the most selective BRS-3 agonist. Second, with peptide 3, substitution of EC3, but also to a less extent EC2, decreased affinity. Third, with the selective BRS-3 ligand, peptide 2, only the substitution of EC3 altered affinity. Fourth, both the affinity of peptides 3 and 4 were affected by differences in the upper transmembrane regions; however, the importance of differences in the upper TM2 and TM3 differed for these two peptides. In particular, for peptide 4, but not peptide 3, differences in the upper TM3 [the presence of an arginine in the TM3 in BRS-3 (Arg127) instead of a glutamine in the equivalent amino acid location in GRPR (Glu121)] was important for affinity. Fifth, these conclusions were supported by the reverse study examining gain-of-affinity GRPR chimeras constructed by inserting the extracellular domains of BRS-3 into GRPR. These results demonstrate that even though these three BRS-3-selective agonists were developed from the same template peptide, [D-Phe 6 ,␤Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14), their molecular determinants of selectivity varied considerably.
These results have similarities and differences from studies of selectivity of Bn peptides for the NMBR/GRPR and other peptide agonists with other G-protein-coupled receptors (GPCRs). Compared with the NMBR and GRPR, our results are similar in that for selectivity of NMB or GRP, with both extracellular and transmembrane regions being important (Fathi et al., 1993a; Akeson et al., 1997; Tokita et al., 2001b; Nakagawa et al., 2005) . Compared with other GPCRs, our results are similar to the peptide agonist, substance P with NK1 receptors (Li et al., 1996) , and CCK-8 with CCK-B receptors (Silvente-Poirot et al., 1998) , where both the extracellular and transmembrane domains are important for selectivity. In contrast, the affinity of CCK-8 for CCK-A receptor (Silvente-Poirot et al., 1998) or secretin for secretin receptors (Holtmann et al., 1995) is determined by the extracellular domains, whereas differences in the transmembrane regions play the critical role in the affinity of nociceptin for orphanin FQ receptors (Meng et al., 1996) .
In terms of the specific extracellular or TM receptor domains important for ligand selectivity, our with BRS-3-selective agonists differ from the location of those determining selectivity of NMB [i.e., in EC3 and EC4 or GRP [critical differences are in EC3 (Tokita et al., 2001b) and in a lesser degree in EC4 and EC2 (Nakagawa et al., 2005) ]. Similar to our results for the most selective BRS-3 ligand, peptide 4, with the mouse opioid receptor and rat AT 1 receptor, the EC2 plays a critical role for high-affinity interaction with the selective peptide [D-Ala 2 ,NMe-Phe 4 ,Gly 5 -ol]-enkephalin (Wang et al., 1995) or angiotensin II (Hjorth et al., 1994) , respectively. Likewise, with CCK B R, both EC2 and EC3 were important for the CCK affinity (Silvente-Poirot et al., 1998) . In contrast, only the TM3 region of the mouse PGD receptor was essential for prostaglandin D 2 binding (Kobayashi et al., 1997 ). These results demonstrate the marked variability in molecular determinants not only for different unrelated receptors but also for closely related receptors for peptide agonists.
Differences in EC2 were the most important for determining the selectivity of peptides 3 and 4, the most selective BRS-3 ligands. Within EC2, there were four amino acid differences between BRS-3 and GRPR and six more differences in the adjacent upper TMs (TM2/TM3). Site-directed mutagenesis demonstrated His107 of BRS-3, instead of Lys101 in GRPR, as the most important difference and, to a lesser extent, Gly112, instead of Arg106, in a comparable position of GRPR in the EC2 as responsible for these peptides' BRS-3 selectivity. Histidine in other GPCRs plays an important role in determining high-affinity interaction/selectivity of various peptide/nonpeptide agonists and/or antagonists (Fong et al., 1993) . Histidine in EC3 of CCK B receptors is necessary for high affinity for CCK (Silvente-Poirot et al., 1998) : in EC1 of AT 1 receptors (Hjorth et al., 1994 ) for angiotensin's high affinity, in TM7 of CCK B receptors for high affinity/potency for CCK (Paillasse et al., 2006) , and in TM3 of corticotropinreleasing factor receptors for the nonpeptide antagonist NBI-27914 (Liaw et al., 1997) . The replacement of His197 in TM5 of neurokinin-1 receptors by lysine results in a 500-fold affinity reduction of the nonpeptide antagonist, CP-96345 (Fong et al., 1993) , suggesting histidine is involved in aminoaromatic interactions with the benzhydryl moiety of CP-96345. It was proposed, the ␦ ϩ amino group of histidine has electrostatic interactions with the benzhydryl ␦(Ϫ)--electrons; however, the longer lysine side chain creates unfavorable positioning for the ligand and decreases the affinity for
